Topical JAK inhibitors
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the EADV Virtual Congress and presented by:
Kamran Ghoreschi, MD
Universitätsmedizin Berlin
Berlin, Germany
The content is produced by Infomedica, the official reporting partner of EADV Virtual Congress. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Prof. Brigitte Dréno, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
References
1. Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019;10:2847.
2. Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 2017;47:1096.
3. Alves de Medeiros AK, Speeckaert R, Desmet E. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. PLoS One 2016;11(10):e0164080.
4. Ng KW. Penetration Enhancement of Topical Formulations. Pharmaceutics 2018;10:51.
5. Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 2017;77:167–70.
6. Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 2017;76:1054–60.
7. Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 2020;145:572–82.
8. Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol 2020;182:1103–10.
